Kisqali (Ribociclib) is approved by the U.S. Food and Drug Administration (FDA) as an initial endocrine-based treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women. It is a Show Full Answer

Kisqali (Ribociclib) is approved by the U.S. Food and Drug Administration (FDA) as an initial endocrine-based treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women. It is a targeted therapy in a class of drugs called cyclin-dependent kinase (CDK) inhibitors.

For Stage 2 breast cancer, treatment may include:
- Surgery
- Lymph node dissection
- Chemotherapy
- Hormonal therapy
- Targeted therapy
- Immunotherapy

The prognosis for Stage 2 breast cancer is favorable, with a five-year survival rate of 86 percent.

For more details, please refer to the specific treatment guidelines provided by your healthcare provider.

 This AI-generated response comes from MyBCTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Stage 2 Breast Cancer: Treatment and Prognosis | MyBCTeam

Kisqali (Ribociclib) for Breast Cancer | MyBCTeam